Published: November 2019

Treatment sequence economic models

Will Green, Project Director, discusses treatment sequence economic models. This video delves into how these models are used to evaluate interventions across patient pathways.

You may also be interested in

Meet the Team: Debs Watkins, a Research Consultant

In this blog we interview Debs Watkins, a Research Consultant at YHEC. We find out how she got into this role, what her day-to-day work looks like, and what she enjoys most about being part of YHEC.

Rare Diseases: The challenges of Demonstrating Value in an Orphan Setting

Securing reimbursement for therapies targeting rare diseases relies on a compelling demonstration of their value. However, the unique challenges inherent in rare disease research often make robust evidence generation an uphill battle. In this blog, Stuart Mealing offers insightful perspectives on the hurdles and strategies for effectively showcasing the value of these vital interventions.

Patient-Reported Outcomes and Rare Diseases: Challenges and Potential Solutions

Drug development and market access is often challenging for rare disease therapies. There are numerous obstacles in the field, such as small and diverse patient populations, which means there is often limited evidence available. YHEC's Andria Joseph explores some of the challenges in rare diseases, specifically relating to patient-reported outcomes, and provides potential solutions for overcoming these.